14088-84-7

Usage

Uses

Used in Coordination Chemistry:
4-CPED is utilized as a ligand for the formation of metal complexes. Its ability to chelate with metal ions makes it a valuable component in the development of coordination compounds, which have applications in areas such as catalysis, materials science, and medicinal chemistry.
Used in Pharmaceutical Compounds Synthesis:
As a precursor, 4-CPED is instrumental in the preparation of nitrogen-containing heterocycles and pharmaceutical compounds. Its structural properties allow for the creation of diverse medicinal agents, contributing to the advancement of drug discovery and development.
Used in Organic Synthesis:
4-CPED serves as a key intermediate in organic synthesis, enabling the production of a wide range of organic molecules. Its reactivity and functional groups make it a useful building block for synthesizing complex organic compounds.
Used in Chemical Research:
In the realm of chemical research, 4-CPED is employed to explore new reaction pathways, investigate the properties of novel compounds, and understand the fundamental aspects of chemical bonding and reactions. Its use in research aids in expanding the knowledge base of chemistry and its applications.
Used in Material Science:
4-CPED finds applications in material science, particularly in the design and synthesis of new materials with specific properties. Its coordination capabilities and ability to form complexes make it a candidate for creating materials with tailored characteristics for various uses.

Upstream product

• 2576-47-8 2-bromoethylamine hydrobromide 
• 106-47-8 4-chloro-aniline 
• 107-15-3 ethylenediamine 
• 24889-92-7 2-((4-chlorophenyl)amino)acetonitrile 
• 79315-03-0 N-(4-chlorolphenyl)-N'-propionylethylenediamine 
• 352-33-0 1-Chloro-4-fluorobenzene 
• 14108-42-0 2-(4-chlorophenyl-1-ylamino)acethydroxamic acid 

Downstream Products

• 61797-06-6 Undec-10-enoic acid (4-chloro-phenyl)-(2-undec-10-enoylamino-ethyl)-amide 
• 717110-23-1 N-[2-(4-chloro-phenylamino)-ethyl]-formamide 
• 50437-74-6 2-phenyl-1-(4-chlorophenyl)-4,5-dihydro-1H-imidazole 
• 1063732-17-1 N-{2-[(4-chlorophenyl)amino]ethyl}-4-[(1,3-thiazol-2-ylamino)sulfonyl]benzamide 
• 1333877-95-4 N-[2-(2,2-dipicolylamino)ethyl]-p-chloroaniline 

Relevant academic research and scientific papers

Phosphorescent Cyclometalated Platinum(II) Imidazolinylidene Complexes

We present the synthesis and characterization of six novel bidentate (Formula presented.) cyclometalated platinum(ii) complexes derived from saturated N-heterocyclic carbene precursors, namely 1-aryl-3-methyl-1H-4,5-dihydroimidazolium salts. The title compounds were then synthesized by a multi-step reaction, which includes an in situ generation of the silver carbene complex, followed by transmetalation to platinum and subsequent introduction of the β-diketonate ligand. Structural characterization by NMR experiments and solid-state structures prove the cyclometalation and the saturated backbone of the NHC motif. Photophysical and electrochemical properties of the platinum(ii) complexes were examined and studied in detail by DFT calculations. The title compounds are strongly emissive at room temperature in the sky-blue region of the visible spectrum and show quantum yields of up to 71 % in a PMMA matrix.

Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors

The discovery/optimization of bis-aryl ureas as Limk inhibitors to obtain high potency and selectivity and appropriate pharmacokinetic properties through systematic SAR studies is reported. Docking studies supported the observed SAR. Optimized Limk inhibitors had high biochemical potency (IC50 400-fold), potent inhibition of cofilin phosphorylation in A7r5, PC-3, and CEM-SS T cells (IC50 1 μM), and good in vitro and in vivo pharmacokinetic properties. In the profiling against a panel of 61 kinases, compound 18b at 1 μM inhibited only Limk1 and STK16 with ≥80% inhibition. Compounds 18b and 18f were highly efficient in inhibiting cell-invasion/migration in PC-3 cells. In addition, compound 18w was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes. Taken together, these data demonstrated that we had developed a novel class of bis-aryl urea derived potent and selective Limk inhibitors.

Control of peroxyoxalate chemiluminescence by nitrogen-containing ligand quenching: Turning off and on by ligand-metal ion host-guest interactions

The control of peroxyoxalate chemiluminescence (PO-CL) by the coordination of nitrogen-containing ligands and metal cations was investigated. Turning the CL off and on was done by PO-CL using 15-monoazacrown-5-tethered anthracene and alkali metal ions. CL quenching and regeneration was also observed in the separated molecular system of 15-monoazacrown-5 and the fluorophores. CL quenching by a number of ligands bearing dipicolylamino groups was evaluated by these PO-CL reactions and found to be closely related to their oxidation potentials, which is dependent on the Weller rate law for electron exchange and this provides strong support for the existence of the CIEEL PO-CL process. When Zn2+ or Cu2+ are added to the PO-CL system quenched by the ligand, N-[2-(2,2′-dipicolylamino)ethyl]aniline, CL was turned on because the electron donating ability of the ligands was modulated. This was controlled by the coordination of the studied metal ions and, therefore, this system results in CL because of host-guest interactions.

Synthesis and study of 1-aryl-1H-4,5-dihydroimidazoles

An easy synthesis of 1-aryl-1H-4,5-dihydroimidazoles 1 by cyclocondensation of N-aryl-N′-formylethylenediamines 2 is described. Such precursors were synthesized by selective formylation of N-arylethylenediamines 3 with p-nitrophenyl formate. Cyclizations were performed using trimethylsilyl polyphosphate. Chemical properties of compounds 1, typical of amidine system, were studied. Reaction of 1 with methyl iodide leads to the corresponding 1-aryl-3-methyl-1H-4,5-dihydroimidazolium salts 5. Reduction of dihydroimidazoles 1 with sodium cyanoborohydride provides a convenient access to N-aryl-N′-methylethylenediamines 4.

Sulfonamide derivatives and drugs containing the same as the active ingredient

The present invention discloses a sulfonamide derivative represented by the following formula (1): [wherein A represents a nitrogen atom, —CH═, etc.; Z represents an oxygen atom, etc.; Ar1represents an aryl group, etc.; Ar2represents an alkyl group, etc.; Rarepresents a hydrogen atom, etc.; Rbrepresents a hydrogen atom, etc.; and Rcrepresents an alkyl group, etc.], or a salt thereof; and drugs containing the derivative or a salt thereof as an active ingredient. This compound exhibits radical scavenging action, gastric mucous secretion augmenting action, and anti-HP action, and thus is effective as a peptic ulcer therapeutic agent.

Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding

A possible bioisosterism between the benzamido and the phenylimidazolidin-2-one moieties has been suggested on the basis of the similarity between the molecular electrostatic potential (MEP) of metoclopramide, a D2 receptor antagonist with weak 5-HT3 receptor antagonist properties, and zetidoline, a D2 receptor antagonist. Starting from this premise, a series of phenylimidazolidin-2-one derivatives bearing a basic azabicycloalkyl or an imidazolylalkyl moiety were synthesized and evaluated for 5-HT3 receptor radioligand binding affinity ([3H]-GR 43694). In vitro 5-HT3 receptor antagonist activity was tested in the guinea pig ileum assay (GPI). A number of high-affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the Bezold-Jarisch reflex in the anesthetized rat. In general, the imidazolylalkyl derivatives were found to be more active than azabicycloalkyls. 1-(3,5-Dichlorophenyl)-3-[(5-methyl-1H-imidazol-4- yl)methyl]imidazolidin-2-one (58), in particular, displayed very high affinity for the 5-HT3 receptor (K(i) of 0.038 nM) with a K(b) of 5.62 nM in the GPI assay, being more potent than the reference compounds (ondansetron, tropisetron, granisetron, and BRL 46470) tested. 58 showed an ID50 comparable to that of ondansetron (2.2 μg/kg iv) in the Bezold-Jarisch reflex. A molecular modeling study based on this structurally novel series of compounds allowed the refinement of previously reported 5-HT3 receptor antagonist pharmacophore models.